NCT04637308View on ClinicalTrials.gov

Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions

Fluid Retention

Interventions

DRUG

Succinylated gelatin

"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Provincial People's Hospital

OTHER

NCT04637308 - Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy | Biotech Hunter | Biotech Hunter